Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler(®) for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes

INTRODUCTION: The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler(®), was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO). METHODS: Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler(®) and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed. RESULTS: A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler(®) use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler(®) from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler(®) as ‘very good’ and > 90.0% of physicians described the Bufomix Easyhaler(®) as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively. CONCLUSION: Twelve weeks’ treatment with the Bufomix Easyhaler(®) resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler(®) was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler(®) in the treatment of adult outpatients with obstructive airway disease. FUNDING: Orion Corp., Orion Pharma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12325-018-0753-6) contains supplementary material, which is available to authorized users.